N/A
N=277
Remote Access to Care, Everywhere, for Parkinson Disease
Parkinson Disease
Bottom Line
View on ClinicalTrials.gov: NCT02144220 ↗Enrolled (actual)
277
Serious AEs
0.0%
Results posted
Jan 2017
Primary outcome: Primary: Feasibility — 91 percentage of visits
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Virtual care visit (Other)
- Age
- Adult, Older Adult · 30+ yrs
- Sex
- All
- Sponsor
- University of Rochester
- Primary completion
- Aug 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Feasibility |
91 | — |
| PRIMARY Change in Quality of Life as Measured by the PDQ-39 Assessment Tool |
0.4 | 0.39 |
| SECONDARY Acceptability |
74 | — |
| SECONDARY Feasibility (Descriptive) |
94 | — |
| SECONDARY Percentage of Patients Who Felt That the Recommendations Improved Their Health |
56 | — |
Summary
The primary objective of this study is to evaluate the feasibility, efficacy and the value of providing care to individuals with Parkinson disease directly into their homes. The specific aims are:
1. To demonstrate the feasibility of conducting remote evaluations of patients with Parkinson disease nationally;
2. To measure the impact of remote care on each patient's ability to improve his or her quality of life (QoL) and better manage his or her Parkinson disease; and
3. To assess the long-term acceptability to patients in receiving ongoing care remotely via telemedicine.
Eligibility Criteria
Inclusion Criteria
- Age greater than 30
- Self reported diagnosis of idiopathic Parkinson disease
- Ability to converse in English
- Ability and willingness to provide informed consent and complete study requirements
- Access to a non-public computer or similar devices with broadband internet.
- Located in New York, Maryland, Delaware, California, or Florida at time of virtual visit (or veterans with Parkinson disease anywhere in the U.S.)
Exclusion Criteria
- Any condition (e.g.prominent psychosis) that in the investigator's or coordinator's judgment would preclude participation.
- Concurrent enrollment in another telemedicine study.
Data sourced from ClinicalTrials.gov (NCT02144220). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.